HER3-DC1

HER3-DC1 is an autologous, type-1-polarized dendritic cell (DC1) cancer vaccine targeting human epidermal growth factor receptor 3 (HER3; ERBB3). Developed originally at the University of Pennsylvania and subsequently by the H. Lee Moffitt Cancer Center and Research Institute, the platform is licensed to ImmunoRestoration. The vaccine is prepared by pulsing patient-derived dendritic cells with MHC class II-binding HER3 multiepitope peptides from both the extracellular and intracellular domains of the HER3 protein. Upon intratumoral, intrathecal, or intradermal administration, HER3-DC1 presents these antigens to CD4+ T helper cells, stimulating a potent anti-HER3 CD4+ Th1 and cytotoxic T-lymphocyte (CTL) immune response. This response alters the tumor microenvironment, promotes immune cell infiltration, and targets HER3-overexpressing cancer cells. HER3-DC1 is currently being evaluated in clinical trials for the treatment of breast cancer, including triple-negative breast cancer (TNBC), HER2-negative breast cancer, and breast cancer-associated brain metastases and leptomeningeal disease.

Other names

anti-HER-3 DC vaccineanti-HER3 DC vaccineanti-HER 3 DC vaccineanti-HER3 DC1 vaccineanti-HER-3 DC1 vaccineanti-HER 3 DC1 vaccineHER3-primed DC vaccineHER-3-primed DC vaccineHER 3-primed DC vaccineHER3-primed DC1 vaccineHER-3-primed DC1 vaccineHER 3-primed DC1 vaccineHER3-primed dendritic cell vaccineHER-3-primed dendritic cell vaccineHER 3-primed dendritic cell vaccine